ADC Therapeutics S.A.
Records under this name other than the patents ADC Therapeutics S.A. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 11 patents it holds.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,736,903 | Pyrrolobenzodiazepine-Anti-Psma Antibody Conjugates now held by MedImmune Limited In force · High confidence | In force | High confidence | |
| US 10,780,181 | Pyrrolobenzodiazepine-Antibody Conjugates now held by MedImmune Limited In force · High confidence | In force | High confidence | |
| US 10,799,596 | Pyrrolobenzodiazepine-Antibody Conjugates now held by MedImmune Limited In force · High confidence | In force | High confidence | |
| US 11,771,775 | Pyrrolobenzodiazepine-Antibody Conjugates now held by MedImmune Limited In force · High confidence | In force | High confidence | |
| US 11,779,650 | Pyrrolobenzodiazepine-Antibody Conjugates now held by MedImmune Limited In force · Medium confidence | In force | Medium confidence | |
| US 9,950,078 | Pyrrolobenzodiazepine-Antibody Conjugates now held by MedImmune Limited In force · Medium confidence | In force | Medium confidence | |
| US 10,544,223 | Combination Therapy with an Anti-Axl Antibody-Drug Conjugate now held by MedImmune Limited In force · High confidence | In force | High confidence | |
| US 11,813,335 | Pyrrolobenzodiazepine-Antibody Conjugates now held by MedImmune Limited In force · High confidence | In force | High confidence | |
| US 11,318,211 | Dosage Regimes for the Administration of an ANTI-CD19 Adc now held by MedImmune Limited In force · High confidence | In force | High confidence | |
| US 11,938,192 | Dosage Regimes for the Administration of an ANTI-CD19 Adc now held by MedImmune Limited In force · Medium confidence | In force | Medium confidence |